Abstract:Hematopoietic stem cell transplantation (HSCT) offers hope and a critical step forward for patients on the tumultuous journey of cancer treatment. With this intervention, a patient typically receives a donor's blood-forming stem cells to repopulate their ablated bone marrow with the goal of cancer remission. This therapy was first harnessed in clinical practice with E. Donnall Thomas' pioneering trial in 1957. Since the 1980s, HSCT has become a standard practice within oncology as a necessary adjunct to chemotherapy, especially in high-risk, relapsed cancer. In the US, the 5-year survival rate for patients with acute and chronic leukemia receiving therapy is 67% with multiple factors impacting survival including cancer type, age at diagnosis, and medical comorbidities. 1 Without treatment, acute leukemia is fatal within months of diagnosis, but relapse-free survival in adult patients with acute myeloid leukemia (AML) is 33% for those receiving chemotherapy only in comparison with 52% for those also receiving HSCT. 2 Although outcomes vary for all patients impacted by hematologic cancers, one fact is clear: access to HSCT is necessary for prolonged survival. Hahn et al 3 have published a new retrospective cohort study examining the implementation of HSCT on varying patient populations who underwent transplant between 2009 and 2018. More than 130 000 transplants were evaluated in patients from childhood to late adulthood. In this 9-year period, utilization of HSCT was shown to increase for people with all diseases and of all ages, races, and ethnicities. Utilization in their study was calculated as the ratio of transplantations to cancer cases. Excitingly, although the rate of implementation for Hispanic patients was less than that of non-Hispanic White patients at the earliest time points in their analysis, by 2018, utilization by Hispanic patients exceeded that by non-Hispanic White patients in the treatment of acute lymphoid leukemia (ALL) and was nearly equal in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). This finding is quite hopeful because despite the many barriers Hispanic patients face when gaining excellent care, which include but are not limited to equitable health insurance access 4 and for some, language barriers, these findings 3 suggest that it is possible for those hurdles to be overcome. Nonetheless, there is still work to do as Hispanic patients still have lower rates of HSCT for AML and NHL at all ages. Disappointingly, while HSCT utilization in Hispanic patients improved over time in many domains, utilization for Black patients with hematologic cancers lags behind non-Hispanic White and Hispanic patients in all diseases with the exception of HL in children and young adults. These findings are exacerbated as these patient populations age. Digesting these findings from Hahn et al 3 necessitates a consideration of the age distribution in the US by race and ethnicity. Although the nation's population is aging with a slowing birth rate, both Hispanic and Black populations were the largest proportion of youth in the country during the time of this study's analysis, which incorporated US census data. From 2009 to 2018, for those aged less than 19 years, 34.6% to 37.7% were Hispanic, 31.6% to 27.6% were Black, 23.1% to 26.2% belonged to other races and ethnicities (including American Indian or Alaska Native, Asian, and Pacific Islander), and 21.2% to 23.1% were White. Older individuals (65-84 years) were predominantly White in America (13.8%-17.7%) followed by American Indian or Alaska Native, Asian, and Pacific Islander (8.2%-11.1%), Black (7.8%-10.5%), and Hispanic (4.9%-6.6%) individuals. Hahn et al 3 report that in cohorts where patients were younger and Hispanic and Black patients formed less of a minority population, HSCT utilization rates were more comparable with White patients. However, in the older cohorts, where Hispanic and Black patients were the minority, HSCT utilization was much worse. This is most apparent when examining cancers among older adults. In childhood, acute leukemia is the main indication for HSCT, while in adulthood, the leading drivers in order of number of transplants per year are multiple myeloma (MM), NHL, AML, myelodysplastic syndrome, ALL, and HL. 5 Hahn et al 3 reveal that although MM has twice the incidence in Black US individuals than White US individuals, utilization of HSCT for MM is 19% higher in White patients. Altogether, these observations from Hahn et al 3 reveal the sobering reality that many patients are inappropriately lacking in access to a necessary life-prolonging treatment. Moreover, the findings revealed here demand further introspection from the medical community as to why this is happening and what can be done to aggressively curtail these disparities. Although we see these disparities -Abstract Truncated-

Disparities in access to hematopoietic cell transplant persist at a transplant center

Improved Access to HCT with Reduced Racial Disparities Through Integration with Leukemia Care and Haploidentical Donors

Donor Socioeconomic Status As a Predictor of Altered Immune Function and Treatment Response Following Hematopoietic Cell Transplantation for Hematologic Malignancy

Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center

Racial disparities in access to liver transplantation in patients with early-stage hepatocellular carcinoma

The health risk of social disadvantage is transplantable into a new host.

Effect of Race on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care

Racial, Ethnic and Socioeconomic Diversity and Outcomes of Patients with Graft-versus-Host Disease: A CIBMTR Analysis

Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort

Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Differences in Racial and Ethnic Disparities Between First and Repeat Kidney Transplantation

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience

Rates of HSCT Transplantation, Racism, and the Aging Face of America

Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience

The importance of equity in transplant oncology

Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Disparities in Liver Transplant Outcomes: Race/Ethnicity and Individual- and Neighborhood-Level Socioeconomic Status